Survival after neuroAIDS

• DOI: 10.1212/wnl.0b013e31820c3089
• Publication Date: 2011-01-20T04:02:26Z
• Authors: E. Lanoy; M. Guiguet; M. Bentata; E. Rouveix; C. Dhiver; I. Poizot-Martin; D. Costagliola; J. Gasnault
• Keywords: Cart

We examined if the CNS Penetration-Effectiveness (CPE) score of antiretroviral drugs was associated with survival after a diagnosis HIV-related encephalopathy, progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis, or cryptococcal meningitis.Using data from FHDH-ANRS CO4, we compared 9,932 HIV-infected patients diagnosed first neurologic AIDS-defining event in pre-combination therapy (cART) (1992-1995), early cART (1996-1998), late (1999-2004) periods. Follow-up subdivided (CPE < 1.5 and CPE ≥ 1.5), relative rates (RR) death were estimated using multivariable Poisson regression models.In pre-cART periods, regimens lower mortality encephalopathy (RR 0.64; 95% confidence interval [CI] 0.47-0.86 RR 0.45; CI 0.35-0.58) PML 0.79; 0.55-1.12 0.31-0.65), to 1.5, while period there no association between mortality. A higher also all periods toxoplasmosis 0.68, 0.56-0.84) meningitis 0.50, 0.34-0.74). Whatever event, these associations not maintained adjustment on updated plasma HIV-RNA (missing, <500, ≥500 copies/mL) ranging 0.82 (95% 0.36-1.91) 1.02 (0.69-1.52).At beginning era, importance for severe period, additional effect vanished more powerful viral load control.